retatrutide phase 3 triumph for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the registrational clinical trials - Giblin - 2026 - Diabetes, Obesity and Metabolism Retatrutide Severe Obesity Trial Shows

They are likely multifactorial and may involve delayed gastric emptying, altered intestinal fluid secretion, and central nervous system effects on gut function

And consult your US physician about next steps for your weight management protocol

One of them involves your 60-day guarantee working when you need it

The study showed a 13% reduction in major adverse cardiovascular events (MACE), a composite endpoint for cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, in patients treated with liraglutide compared with placebo at a mean follow-up of 3.8 years (hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.780.97) and a significant reduction in cardiovascular death (HR 0.78, 95% CI 0.660.93)

Extended Data Fig

inclusion of more healthy options, changes to portion sizes etc.)